Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Phase 3 trial of (177)Lu-DOTATATE for midgut neuroendocrine tumors.N Engl J Med. 2017; 376: 125-135
- (177)Lu-DOTATATE plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2021; 22: 1752-1763
- Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.Ann Oncol. 1999; 10: S23-S29
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2013; 40: 800-816
- Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2004; 31: 1038-1046
- [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.Int J Cancer. 2001; 92: 628-633
- Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.Eur J Nucl Med Mol Imaging. 2003; 30: 417-422
- Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-DOTATATE in the phase III NETTER-1 trial.J Clin Oncol. 2018; 36: 2578-2584
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-DOTATATE: an analysis of the NETTER-1 study.Eur J Nucl Med Mol Imaging. 2020; 47: 2372-2382
- Long-term results of PRRT in advanced bronchopulmonary carcinoid.Eur J Nucl Med Mol Imaging. 2016; 43: 441-452
- 1335TiP - COMPETE trial: peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET.Ann Oncol. 2018; 29: viii478
- State of the art and future directions in the systemic treatment of neuroendocrine neoplasms.Curr Opin Oncol. 2021; 33: 378-385
- Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.J Clin Oncol. 2022; 40: TPS514-TPS
- Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.Eur J Nucl Med Mol Imaging. 2021; 49: 54-63
- Targeted alpha therapy with bismuth-213 and actinium-225: meeting future demand.J Labelled Comp Radiopharm. 2019; 62: 794-802
- Liver-directed therapy for neuroendocrine metastases: from interventional radiology to nuclear medicine procedures.Cancers (Basel). 2021; 13: 6368
- Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.BMC Cancer. 2019; 19: 788
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.Eur J Nucl Med Mol Imaging. 2015; 42: 5-19
- Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.J Nucl Med. 2013; 54: 1857-1861
- Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.Endocr Relat Cancer. 2010; 17: R53-R73
- Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs.J Glob Oncol. 2017; 3: 43-53
- Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.BMC Cancer. 2019; 19: 274
- Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology.Mayo Clin Proc. 2019; 94: 2291-2301
- Defining quality of life: a wild-goose chase?.Eur J Psychol. 2013; 9: 185-203
- Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.J Clin Oncol. 2016; 34: 557-565
- Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.Eur J Cancer Care (Engl). 2013; 22: 714-725
- Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982; 5: 649-655
- The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.J Natl Cancer Inst. 1993; 85: 365-376
- The functional assessment of cancer therapy scale: development and validation of the general measure.J Clin Oncol. 1993; 11: 570-579
- Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours.Br J Cancer. 2013; 108: 301-310
- Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors.Pancreas. 2009; 38: e87-e95
- Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.J Clin Oncol. 2008; 26: 2124-2130
- Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.Eur J Nucl Med Mol Imaging. 2018; 45: 38-46
- Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]Octreotate.J Nucl Med. 2011; 52: 1361
- Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management.World J Gastroenterol. 2020; 26: 2305-2322
- Consensus on biomarkers for neuroendocrine tumour disease.Lancet Oncol. 2015; 16: e435-e446
- The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.Endocr Pathol. 2003; 14: 3-23
- Chromogranin A: any relevance in neuroendocrine tumors?.Curr Opin Endocrinol Diabetes Obes. 2016; 23: 28-37
- Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate.Endocr Relat Cancer. 2017; 24: 243-251
- Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.Scand J Gastroenterol. 2014; 49: 942-949
- Elevated serum levels of chromogranin A in hepatocellular carcinoma.BMC Surg. 2012; 12: S7
- Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis.Asian J Androl. 2018; 20: 561-566
- Chromogranin A: a valuable serum diagnostic marker for non-insulinoma neuroendocrine tumors of the pancreas in a Chinese population.Med Sci Monit. 2020; 26: e926635
- Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.Ann Oncol. 2009; 20: iv150-iv153
- Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer.Cancer. 1990; 65: 1386-1390
- Serum neuron-specific enolase independently predicts outcomes of patients with Merkel cell carcinoma.Br J Dermatol. 2022; 187: 806-808
- Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.J Clin Endocrinol Metab. 1997; 82: 2622-2628
- Prognostic utility of 24-hour urinary 5-HIAA doubling time in patients with neuroendocrine tumors.Endocr Pract. 2018; 24: 710-717
- Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.Am J Med. 1986; 81: 41-48
- Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement.Ann Clin Biochem. 2016; 53: 554-560
- ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers.Neuroendocrinology. 2017; 105: 201-211
- Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center.Ann Oncol. 1997; 8: 685-690
- Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.Cancer Imaging. 2020; 20: 57
- Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.Endocr Relat Cancer. 2015; 22: 561-575
- Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer.Biomarkers. 2014; 19: 34-42
- Liquid biopsy in chronic liver disease.Ann Hepatol. 2021; 20: 100197
- PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.Eur J Nucl Med Mol Imaging. 2020; 47: 895-906
- The NETest: the clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors.Endocrinol Metab Clin North Am. 2018; 47: 485-504
- The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.PLoS One. 2013; 8: e63364
- Assessment of NETest clinical utility in a U.S. Registry-based study.Oncologist. 2019; 24: 783-790
- NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and Identifies progressive disease.Neuroendocrinology. 2019; 108: 219-231
- PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy.Eur J Nucl Med Mol Imaging. 2018; 45: 1155-1169
- Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast.Radiology. 2006; 241: 441-448
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009; 45: 228-247
- Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.Endocr Relat Cancer. 2014; 21: R105-R120
- Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?.BMC Cancer. 2017; 17: 154
- Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).Br J Cancer. 2019; 121: 537-544
- Comparison of CHOI, RECIST and somatostatin receptor PET/CT based criteria for the evaluation of response and response prediction to PRRT.Pharmaceutics. 2022; 14: 1278
- Hidden figures: occult intra-cardiac metastases in asymptomatic neuroendocrine tumor patients.J Oncol Cancer Res. 2018; 2: 23-27
- Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours.Endocr Relat Cancer. 2018; 25: 245-254
- Evolution of the mesenteric mass in small intestinal neuroendocrine tumours.Cancers (Basel). 2021; 13: 443
- CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.AJR Am J Roentgenol. 2004; 183: 1619-1628
- Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate).AJR Am J Roentgenol. 2002; 179: 1059-1062
- Advances in oncological treatment: limitations of RECIST 1.1 criteria.Q J Nucl Med Mol Imaging. 2018; 62: 129-139
- Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single Institution with imatinib mesylate: proposal of new computed tomography response criteria.J Clin Oncol. 2007; 25: 1753-1759
- A delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management.Endocr Connect. 2016; 5: 174-187
- Endocrine pancreatic tumours and helical ct: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival.Pancreatology. 2006; 6: 77-85
- Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection.Pancreatology. 2016; 16: 397-402
- Tumor contrast-enhancement for monitoring of PRRT (177)Lu-DOTATATE in pancreatic neuroendocrine tumor patients.Front Oncol. 2020; 10: 193
- Randomized run-in study of bevacizumab (B) and everolimus (E) in low-to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker.J Clin Oncol. 2010; 28: 4002
- Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy.Am J Roentgenol. 2011; 196: 569-576
- Early prediction of treatment response of neuroendocrine hepatic metastases after peptide receptor radionuclide therapy with (90)Y-DOTATOC using diffusion weighted and dynamic contrast-enhanced MRI.Contrast Media Mol Imaging. 2019; 2019: 1517208
- Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response.Radiology. 2012; 263: 139-148
- SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework.J Nucl Med. 2018; 59: 1085-1091
- Efficacy and safety of (177)Lu-DOTATATE in lung neuroendocrine tumors: a bicenter study.J Nucl Med. 2022; 63: 218-225
- Prognostic value of 68Ga-DOTANOC PET/CT SUVmax in patients with neuroendocrine tumors of the pancreas.J Nucl Med. 2015; 56: 1843-1848
- SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors.Mol Imaging Biol. 2015; 17: 313-318
- Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET/CT parameters in metastatic advanced neuroendocrine tumor patients treated with PRRT.Cancers (Basel). 2022; 14: 592
- 68)Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours.Radiother Oncol. 2019; 141: 108-115
- Quantitative (68)Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with (177)Lu-DOTATATE.J Nucl Med. 2021; 62: 1406-1414
- Integrating early rapid post-peptide receptor radionuclide therapy quality assurance scan into the outpatient setting.J Nucl Med Radiat Ther. 2019; 10: 395
- Post-PRRT scans: which scans to make and what to look for.Cancer Imaging. 2022; 22: 29
- Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA.Eur J Nucl Med Mol Imaging. 2017; 44: 1588-1601
- Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2021; 19: 839-868
- Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.Radiographics. 2015; 35: 500-516
- Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.Cancer Imaging. 2018; 18: 3
- The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.Eur J Nucl Med Mol Imaging. 2012; 39: 50-56
- "Tumour sink effect" on the diagnostic or posttreatment radioiodine scan due to sequestration into large-volume functioning metastasis of differentiated thyroid carcinoma influencing uptake in smaller metastatic sites or remnant thyroid tissue: an uncommon but possible phenomenon in thyroid cancer practice.World J Nucl Med. 2020; 19: 141-143
- Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2013; 40: 881-888
- Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.Nucl Med Commun. 2016; 37: 1030-1037
- Clinical utility of (18)F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis.Cancers (Basel). 2021; 13: 1813
- Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.Endocr Relat Cancer. 2008; 15: 1083-1097
- Prognostic factors in gastrointestinal endocrine tumors.Endocr Pathol. 2007; 18: 145-149
- Recommendations for management of patients with neuroendocrine liver metastases.Lancet Oncol. 2014; 15: e8-e21
- Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.Endocrine. 2014; 47: 177-182
- Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.Cardiovasc Intervent Radiol. 2012; 35: 334-342
- Non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors.J Clin Med. 2019; 8: 1907
- Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation.Eur Radiol. 2013; 23: 805-815
- PET/MRI of hepatic 90Y microsphere Deposition Determines individual tumor response.Cardiovasc Intervent Radiol. 2016; 39: 855-864
- GEP-NET radiomics: a systematic review and radiomics quality score assessment.Eur Radiol. 2022; 32: 7278-7294
Article info
Footnotes
The authors have no conflic of interest related to the present work.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
